

# Somatic Mutations in p85 $\alpha$ Promote Tumorigenesis through Class IA PI3K Activation

Bijay S. Jaiswal,<sup>1</sup> Vasantharajan Janakiraman,<sup>1</sup> Noelyn M. Kljavin,<sup>1</sup> Subhra Chaudhuri,<sup>1</sup> Howard M. Stern,<sup>2</sup> Weiru Wang,<sup>3</sup> Zhengyan Kan,<sup>1</sup> Hashem A. Dbouk,<sup>7</sup> Brock A. Peters,<sup>1</sup> Paul Waring,<sup>2</sup> Trisha Dela Vega,<sup>3</sup> Denise M. Kenski,<sup>1</sup> Krista K. Bowman,<sup>3</sup> Maria Lorenzo,<sup>4</sup> Hong Li,<sup>4</sup> Jiansheng Wu,<sup>4</sup> Zora Modrusan,<sup>1</sup> Jeremy Stinson,<sup>1</sup> Michael Eby,<sup>5</sup> Peng Yue,<sup>6</sup> Josh S. Kaminker,<sup>6</sup> Frederic J. de Sauvage,<sup>1</sup> Jonathan M. Backer,<sup>7</sup> and Somasekar Seshagiri<sup>1,\*</sup>

<sup>1</sup>Department of Molecular Biology

<sup>2</sup>Department of Pathology

<sup>3</sup>Department of Protein Engineering

<sup>4</sup>Department of Protein Chemistry

<sup>5</sup>Department of Translational Oncology

<sup>6</sup>Department of Bioinformatics

Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

<sup>7</sup>Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

\*Correspondence: [sekar@gene.com](mailto:sekar@gene.com)

DOI 10.1016/j.ccr.2009.10.016

## SUMMARY

Members of the mammalian phosphoinositide-3-OH kinase (PI3K) family of proteins are critical regulators of various cellular process including cell survival, growth, proliferation, and motility. Oncogenic activating mutations in the p110 $\alpha$  catalytic subunit of the heterodimeric p110/p85 PI3K enzyme are frequent in human cancers. Here we show the presence of frequent mutations in p85 $\alpha$  in colon cancer, a majority of which occurs in the inter-Src homology-2 (iSH2) domain. These mutations uncouple and retain p85 $\alpha$ 's p110-stabilizing activity, while abrogating its p110-inhibitory activity. The p85 $\alpha$  mutants promote cell survival, AKT activation, anchorage-independent cell growth, and oncogenesis in a p110-dependent manner.

## INTRODUCTION

Phosphoinositide 3-kinase (PI3K) family of lipid kinases are divided into three major classes based on primary sequence, substrate preference, and regulation (Cantley, 2002; Engelman et al., 2006; Fruman et al., 1998; Hawkins et al., 2006). While class IA PI3Ks are heterodimeric enzymes composed of a catalytic subunit (p110 $\alpha$ , p110 $\beta$ , or p110 $\delta$ ) complexed with one of five regulatory subunits (p85 $\alpha$ , p55 $\alpha$ , p50 $\alpha$ , p85 $\beta$ , or p55 $\gamma$ ), the class IB enzyme is a dimer made of p110 $\gamma$  catalytic subunit and p101 or p84 regulatory subunit (Cantley, 2002; Hawkins et al., 2006; Vanhaesebroeck et al., 2005). The class I catalytic subunit polypeptides p110 $\alpha$ , p110 $\beta$ , p110 $\delta$ , and p110 $\gamma$  are encoded by *PIK3CA*, *PIK3CB*, *PIK3CD*, and *PIK3CG*, respectively (Cantley, 2002; Vanhaesebroeck and Waterfield, 1999). The regulatory subunits are encoded by five genes: *PIK3R1* codes p85 $\alpha$ ,

p55 $\alpha$ , and p50 $\alpha$ ; *PIK3R2* codes p85 $\beta$ ; *PIK3R3* codes p55 $\gamma$ ; *PIK3R5* codes p101; and *PIK3R6* codes p84 (Cantley, 2002; Vanhaesebroeck and Waterfield, 1999).

The p110 catalytic subunits of PI3K share a common domain architecture consisting of an N-terminal adaptor binding domain that binds to p85 regulatory subunits, a Ras binding domain, a putative membrane binding C2 domain, a helical region that makes a regulatory contact with the p85 nSH2 domain (Miled et al., 2007), and a C-terminal kinase domain. Similarly, the p85 regulatory subunits have in common an N-terminal SH3 domain, a domain homologous to the Rho GTPase-activating protein domain of the BCR gene product (BCR domain), and two SH2 domains (nSH2 and cSH2) that flank an intervening antiparallel coiled-coil (iSH2) required for binding to the adaptor binding domain in p110 (Holt et al., 1994). Besides its role in inhibiting the catalytic activity of p110, in the basal state, the

## SIGNIFICANCE

Somatic mutations in the catalytic p110 $\alpha$  subunit of PI3K are common in cancers. In this study, we show the occurrence of frequent mutations in the regulatory p85 $\alpha$  subunit of PI3K in human cancers. Our data demonstrate an alternate mechanism for PI3K pathway activation and oncogenesis resulting from the impaired regulation of p110 activity by mutant p85 $\alpha$ . Further, p85 $\alpha$  mutations are likely to be useful as diagnostic markers for identification of p110-dependent tumors that may not carry an activating p110 $\alpha$  mutation, but are candidates for targeted treatment with PI3K pathway inhibitors that are in development.

p85 regulatory subunit is required to stabilize the catalytic p110 subunit (Kodaki et al., 1994; Yu et al., 1998). Upon growth factor stimulation, the nSH2 and cSH2 domains of p85 bind to phosphorylated tyrosines (YXXM motif) in activated receptors and adaptors that activate catalytic p110 (Backer et al., 1992; Carpenter et al., 1993; Otsu et al., 1991). Once activated, PI3Ks phosphorylate phosphoinositide 4,5-bisphosphate leading to the production of phosphoinositide 3,4,5-triphosphate, which serves as an important second messenger that regulates cell survival, growth, proliferation, and motility through a variety of downstream effectors (Cantley, 2002; Carpenter et al., 1993; Engelman et al., 2006; Jimenez et al., 2002; Vanhaesebroeck and Waterfield, 1999; Yu et al., 1998).

Several studies have identified common somatic mutations in *PIK3CA* in cancers of colon, rectum, breast, ovary, brain, and liver (Bader et al., 2005; Samuels et al., 2004). Several *PIK3CA* mutants, including hotspot mutations in the helical and kinase domain, show elevated lipid kinase activity in vitro and induce oncogenic transformation in vivo (Gymnopoulos et al., 2007; Ike-noue et al., 2005; Isakoff et al., 2005; Kang et al., 2005; Samuels et al., 2004; Zhao and Vogt, 2008). While oncogenic p110 $\alpha$  mutations are common in cancers (Bader et al., 2005; Samuels et al., 2004), such mutations in the regulatory p85 subunit are not as common (Bader et al., 2005; Hennessy et al., 2005). Previously, a truncated form of p85 $\alpha$  containing residues 1–571 fused to a fragment of Eph (p65) was identified in an X-ray-irradiated mouse lymphoma model (Borlato et al., 2000; Chan et al., 2002; Jimenez et al., 1998). However, this mutation has so far not been found in human cancers. Although, a p85 $\alpha$  truncation mutant was described in a human lymphoma cell line (Jucker et al., 2002), its relevance in oncogenesis is not clear (Horn et al., 2008). A low prevalence of p85 $\alpha$  mutation in breast (Wood et al., 2007), colon (Philp et al., 2001), and ovarian (Philp et al., 2001) tumors has been reported, but the functional role of these mutations in tumorigenesis is not known. Recently, frequent occurrence of p85 $\alpha$  mutations in glioblastoma was reported (Parsons et al., 2008; TCGA, 2008). However, the ability and role of these mutations in promoting oncogenesis remains to be studied.

In this study we have systematically sequenced a large number of tumors and found mutations in p85 $\alpha$  that uncouple its p110-inhibitory effects from the stabilization activity, leading to p110-mediated survival signaling and oncogenesis.

## RESULTS


### Identification of PI3K Regulatory Subunit Mutations

We sequenced coding exons and an ~50 bp region flanking the exons of *PIK3R1*, *PIK3R2*, *PIK3R3*, *PIK3R4*, and *PIK3R5* regulatory subunits of PI3K in primary human cancers. A total of 672 human primary tumor samples consisting of 213 non-small-cell lung, 108 colorectal, 62 breast, 87 renal cell, 46 ovary, 40 skin (melanomas), 37 gastric, 21 small-cell lung, 16 esophageal, 13 bladder, 12 chronic lymphocytic leukemia, 11 hepatocellular, and 6 pancreatic cancers were analyzed (see Table S1 available online). We found that *PIK3R1*, which codes for p85 $\alpha$ , was mutated in 9 of 108 colorectal (8%), 1 of 62 breast (2%), and 1 of 6 pancreatic (17%) tumor samples (Figure 1, Figure S1, and Tables S1 and S2). All the mutations were confirmed to be

somatic by their presence in the original tumor DNA and absence in the matched adjacent normal tissue through additional sequencing or mass spectrometric analysis (Figures S1 and S2). A majority of the mutations identified were amino acid substitutions that clustered in the iSH2 domain. Interestingly, one of the mutated residues, N564, was within hydrogen bonding distance of p110 $\alpha$  C2 domain residue N345 (Huang et al., 2007; Figures 1A and 1C). Substitutions at residue N345 of p110 $\alpha$  are oncogenic (Gymnopoulos et al., 2007), probably due to destabilization of iSH2-C2 inhibitory interactions. Therefore, it is likely that the p85 $\alpha$  N564D mutation mimics the effect of N345 substitutions in p110 $\alpha$ . Interestingly, both N564 and an adjacent residue, D560 of p85 $\alpha$ , which is also within hydrogen bonding distance of N345 of p110 $\alpha$ , were recently reported to be mutated in glioblastoma (TCGA, 2008). Though the potential effect of these substitutions on relieving the inhibitory contacts have been proposed (TCGA, 2008), the actual functional consequence of the mutation and its role in oncogenesis have not been explored. The regulatory p85 $\alpha$  subunit, besides regulating p110 $\alpha$ , also regulates p110 $\beta$  and p110 $\delta$  (Engelman et al., 2006; Vanhaesebroeck et al., 2005). A similar set of regulatory contacts, involving residue N344 in p110 $\beta$  and residue N334 p110 $\delta$ , analogous to p110 $\alpha$  residue N345, and p85 $\alpha$  iSH2 residues N564 and D560, has been previously proposed (Amzel et al., 2008). Our modeling of the C2 domain of p110 $\beta$  and p110 $\delta$  supports these regulatory interactions (Figure 1C), suggesting that the p85 $\alpha$  mutations may lead to general activation of all class IA catalytic subunits.

In addition to mutations that clustered in iSH2, we identified mutations in the cSH2 domain, specifically a mutation in residue R649, which is part of the conserved FLVERS motif required for phosphotyrosine engagement (Hoedemaeker et al., 1999). The R649 mutation is likely to alter the activity of the protein, given that analogous conserved Arg residues within SH2 domains of other proteins are mutated in multiple human diseases (Figure S3). Mutations in the nSH2 and BCR domains and in the spacer between those domains were also identified (Figure 1A). It is noteworthy that the majority of the mutated residues identified within nSH2, iSH2, and cSH2 were conserved across the p85 family (Figure 1 and Figure S4). Meta-analysis of mutations in p85 $\alpha$  (Jimenez et al., 1998; Jucker et al., 2002; Parsons et al., 2008; Philp et al., 2001; TCGA, 2008; Wood et al., 2007) revealed several recurrent mutation sites that include R348, G376, L380, K459, D560, N564, and R574. Interestingly, these mutated sites are conserved across the three closely related p85 family members (p85 $\alpha$ /p55 $\alpha$ /p50 $\alpha$ , p85 $\beta$ , and p55 $\gamma$ ), suggesting that these mutations are likely to have a functional role in oncogenesis. We also detected mutations in *PIK3R2* (p85 $\beta$ ) and two additional regulatory subunits, *PIK3R4* (p150) and *PIK3R5* (p101), albeit at much lower frequencies (Figure S5 and Tables S2 and S3).

In addition to sequencing PI3K regulatory subunit genes, we tested the tumor samples for somatic mutations in *PIK3CA*, *KRAS*, and *PTEN*. In colon tumor bearing p85 $\alpha$  mutations, we rarely found *KRAS* or *PTEN* mutations. However, ~45% of p85 $\alpha$  mutant colon tumor samples had *PIK3CA* mutations, suggesting that the p110 $\alpha$  and p85 $\alpha$  mutations are not always mutually exclusive in this tumor type (Figure 1D, Figure S6, and Tables S2 and S3). Unlike in colon cancer, published *PIK3R1* mutation




**Figure 1. p85 $\alpha$  Mutations in Human Cancer**

(A) Cartoon depicting the p85 $\alpha$  somatic mutations. Horizontal bar below mutated residues indicates conserved residues across the p85 family members (R1–R3). Black and orange vertical bars indicate previously identified p85 $\alpha$  mutations (Jimenez et al., 1998; Jucker et al., 2002; Parsons et al., 2008; Philp et al., 2001; TCGA, 2008; Wood et al., 2007). Orange bars signify hotspots, with the bar height drawn proportional to number of times the residue/region has been altered. 1, TCGA, 2008; 2, Parsons et al., 2008; 3, Jimenez et al., 1998.

(B) p85 $\alpha$  somatic mutations modeled on a recent crystal structure (PDB code 2RD0) of p85 $\alpha$  iSH2 domain in complex with p110 $\alpha$  (Huang et al., 2007). Blue patches on the surface of p110 $\alpha$  represent regions that are <3.5 Å from p85 $\alpha$  iSH2.

(C) The p85 $\alpha$  residues, N564 and D560, within hydrogen bonding distance of N345 of p110 $\alpha$  (Huang et al., 2008; TCGA, 2008) located in the C2 domain are shown. Models of p110 $\beta$  (yellow) and p110 $\delta$  (purple) C2 domains superimposed on p110 $\alpha$  C2 domain (cyan) illustrates the proximity of conserved residue N344 of p110 $\beta$  and N334 of p110 $\delta$  (corresponding to N345 of p110 $\alpha$ ) and p85 $\alpha$  iSH2 residues D560 and N564.

(D) Mutation map of tumors carrying changes in one or more of the genes studied. Each column corresponds to a tumor sample. Pc, pancreatic cancer.



### Figure 2. p85 $\alpha$ Mutants Interact with p110 $\alpha$ and Stabilize p110 $\alpha$

(A–D) HA-tagged p85 $\alpha$  mutants and wild-type p85 $\alpha$  that carry an intact p110 $\alpha$  interaction domain immunoprecipitate p110 $\alpha$  from Cos7 cells transfected with the constructs indicated in the panels. Expression of all the transfected constructs was confirmed in the lysates as shown below in each of the panels. The dominant-negative p85 $\Delta$  and empty vector-transfected cells served as controls.

(E) p85 $\alpha$  mutants that contain an intact p110 $\alpha$  binding domain when transiently expressed in pan-p85 null MEFs stabilize p110 $\alpha$  levels.

data shows that it is mutually exclusive with *PIK3CA* mutations in glioblastoma (Parsons et al., 2008; TCGA, 2008), although the frequency of *PIK3CA* mutations in glioblastoma is known to be low (Hartmann et al., 2005) compared with colon cancers (Bader et al., 2005; Table S2). *PTEN* mutations generally are rare in colon cancers (Wang et al., 1998), but co-occurred with *PIK3R1* mutations in two of our samples (Table S3). In a similar analysis of the published glioblastoma data, we found only one of the *PIK3R1* mutations to co-occur with *PTEN* mutation, even though *PTEN* mutations are quite frequent in glioblastomas (Parsons et al., 2008; TCGA, 2008; Yin and Shen, 2008).


### p85 $\alpha$ Mutants Interact with and Stabilize p110 $\alpha$

To understand the function of p85 $\alpha$  mutations, we tested them for their ability to interact with p110 $\alpha$ . In coimmunoprecipitation experiments using COS-7 cells, we found that overexpressed HA-tagged p85 $\alpha$  wild-type and point mutants that contained an intact p110-binding domain (Dhand et al., 1994; Huang et al., 2007; Miled et al., 2007) were able to interact with p110 $\alpha$  (Figure 2A). Similarly, p85 $\alpha$  mutants with a short insertion (H669insLKH), a short deletion (QYL579delL), or a premature stop (R642\*) were all able to interact with p110 $\alpha$ , as demonstrated by the presence of p110 $\alpha$  in the immunoprecipitated p85 $\alpha$  (Figures

2B and 2D). Additionally, the C2-iSH2 interaction region mutants D560Y and D560Y\_N564D were able to interact with p110 $\alpha$  (Figure 2C). As previously described, a truncated p85 mutant, Q572\*, was also able to interact with p110 $\alpha$  (Shekar et al., 2005). However, p85 $\alpha$  mutants that lacked the p110 $\alpha$  binding region, namely R162\*, L380fs, R348\*, and a dominant-negative mutant, p85 $\Delta$  (Dhand et al., 1994), all failed to interact with p110 $\alpha$  (Figure 2). As expected, the mock and vector control lanes in the assay did not immunoprecipitate HA-p85 $\alpha$  or p110 $\alpha$ , confirming the specificity of the p85 $\alpha$ -p110 $\alpha$  interactions observed.

Given that most of the p85 $\alpha$  mutants still could interact with p110 $\alpha$ , we next tested their ability to stabilize p110 $\alpha$  protein levels in immortalized pan-p85 null MEFs. It was previously shown that the endogenous levels of p110 $\alpha$  in the pan-p85 null background are significantly reduced but can be restored by reconstituting these cells with wild-type p85 (Brachmann et al., 2005). We focused primarily on testing p85 $\alpha$  iSH2 domain mutants for their ability to stabilize p110 $\alpha$ , given that the majority of the mutations identified clustered within this domain. As with wild-type p85 $\alpha$ , all of the p85 $\alpha$  mutants that contained an intact p110 $\alpha$ -binding domain stabilized p110 $\alpha$  (Figure 2E). Consistent with their inability to bind p110 $\alpha$ , L380fs and the dominant-negative p85 $\Delta$  did not stabilize p110 $\alpha$  (Figure 2E).





**Figure 3. p85 $\alpha$  Mutants Interact with p110 $\beta$  and p110 $\delta$**

(A and B) Indicated HA-tagged p85 $\alpha$  mutants and wild-type p85 $\alpha$  cotransfected with myc-p110 $\beta$  (A) or myc-p110 $\delta$  (B)-immunoprecipitated p110 $\beta$  (A) or p110 $\delta$  (B). Expression of all the transfected constructs was confirmed in the lysates. The dominant-negative p85 $\alpha$  and empty vector-transfected cells served as controls.

### p85 $\alpha$ Mutants Interact with p110 $\beta$ and p110 $\delta$

The p85 $\alpha$  regulatory subunit associates with and regulates all class IA PI3K members including p110 $\beta$  and p110 $\delta$  (Chantry et al., 1997; Engelman et al., 2006; Hu et al., 1993; Vanhaesebroeck et al., 2005). Hence, we tested the ability of myc-tagged p110 $\beta$  or p110 $\delta$  to interact with a subset of p85 $\alpha$  mutants predicted to destabilize the C2-iSH2 interactions (Figure 1C). We found that overexpressed HA-tagged p85 $\alpha$  wild-type, D560Y, N564D, D560Y\_N564D, QYL579delL, and Q572\*, all of which contained an intact p110-binding domain (Dhand et al., 1994; Huang et al., 2007; Miled et al., 2007), were able to interact with both p110 $\beta$  and p110 $\delta$  (Figures 3A and 3B). However, as expected, dominant-negative mutant p85 $\Delta$  (Dhand et al., 1994) and the mock and vector control lanes did not immunoprecipitate p110 $\beta$  or p110 $\delta$  (Figures 3A and 3B), confirming the specificity of the p85-p110 $\beta/\delta$  interactions observed.

### Mutant p85 $\alpha$ /p110 Class IA PI3K Holoenzymes Are More Active

Having established that the p85 $\alpha$  mutants can interact with p110 $\alpha$ , p110 $\beta$ , and p110 $\delta$ , we tested if the mutations altered the ability of p85 $\alpha$  to suppress the activity of the catalytic subunit. In order to study this, we expressed, purified, and tested heterodimeric p85 $\alpha$ /p110 class IA PI3K wild-type or mutant enzymes for their lipid kinase activity. The mutants tested were selected based on the stabilization activity data (Figure 2E), the transient cell survival analysis (Figure S7), the structural relevance of p85 $\alpha$  N564 (Huang et al., 2007) mutation, and the proximity of QYL579delL mutation to the oncogenic murine Q572\* mutation (Jimenez et al., 1998).


In testing the PI3K activity of purified recombinant iSH2 domain mutant p85 $\alpha$ /p110 $\alpha$  holoenzyme, we found that relative to the wild-type p85 $\alpha$ /p110 $\alpha$ , the N564D mutant and QYL579 delL iSH2 p85 mutant had ~1.7- to 2.0-fold increase in activity as measured by an *in vitro* phosphatidylinositol (PI) phosphorylation assay (Knight et al., 2007; Figures 4A and 4B). As expected, the murine Q572\* mutant (Chan et al., 2002; Jimenez et al., 1998; Shekar et al., 2005) showed increased kinase activity compared with the wild-type. We further tested the p85 $\alpha$  mutants in an alternate assay using nSHi proteins composed of a minimal p85 $\alpha$  wild-type fragment that spans the nSH2 and iSH2 (amino acids 320–600) domains (Shekar et al., 2005). This minimal nSHi wild-type p85 $\alpha$  protein is known to inhibit overexpressed p110 $\alpha$  activity in cell lysates (Shekar et al., 2005). Consistent with the holoenzyme activity observed, mutant nSHi proteins showed decreased p110 $\alpha$  activity inhibition (Figure S8). Despite

the increased PI3K activity, the mutant p85 $\alpha$ /p110 $\alpha$  holoenzymes were effectively inhibited by a p110 $\alpha/\delta$  inhibitor (Folkes et al., 2007).

Having established the elevated lipid kinase activity of mutant p85 $\alpha$ /p110 $\alpha$  holoenzyme, we next measured the PI3K activity of purified recombinant iSH2 domain wild-type or mutant p85 $\alpha$ /p110 $\beta$  and p85 $\alpha$ /p110 $\delta$  holoenzymes. We found that relative to the wild-type p85 $\alpha$ /p110 $\beta$ , the N564D and QYL579delL iSH2 p85/p110 $\beta$  mutant enzymes had ~1.6- to 1.8-fold increase in activity as measured by an *in vitro* PI phosphorylation assay (Knight et al., 2007; Figures 4C and 4D). Similarly, relative to wild-type p85 $\alpha$ /p110 $\delta$  holoenzyme, the N564D mutant and QYL579 delL iSH2 p85/p110 $\delta$  mutant enzymes showed elevated lipid kinase activity (~1.2-fold) although the increase in lipid kinase activity was low compared to p85 $\alpha$ /p110 $\alpha$  or p85 $\alpha$ /p110 $\beta$  mutant holoenzymes (Figures 4E and 4F). Consistent with the impaired inhibition by the p85 $\alpha$  mutants across all the class IA catalytic subunits, the murine mutant Q572\* p85 $\alpha$ /p110 $\beta$  and p85 $\alpha$ /p110 $\delta$  enzymes also showed increased kinase activity compared with the wild-type enzyme (Figures 4A–4F). Similar to mutant p85 $\alpha$ /p110 $\alpha$  enzymes, the lipid kinase activity of mutant p85 $\alpha$ /p110 $\beta$  or p85 $\alpha$ /p110 $\delta$  was effectively inhibited by a p110 $\beta$  (Jackson et al., 2005) or p110 $\alpha/\delta$  inhibitor (Folkes et al., 2007), respectively (Figures 4C–4F and Figure S9), indicating that pan-p110 class IA inhibitors are likely to be efficacious in patients with p85 $\alpha$  mutations.

### p85 $\alpha$ Mutants Promote AKT Activation and Cell Survival

In order to further understand the functional relevance of the p85 $\alpha$  mutations we investigated their ability to render the IL-3-dependent murine BaF3 cells growth factor independently by stably expressing the iSH2 mutants either alone or in combination with wild-type p110 $\alpha$ , p110 $\beta$ , or p110 $\delta$ . We additionally tested a glioblastoma iSH2 domain mutant, D560Y, and a synthetic-iSH2 double mutant, D560Y\_N564D, for their ability to promote IL-3-independent growth of BaF3 cells. Stable expression of the HA-tagged p85 $\alpha$  mutants either alone or together with myc-tagged p110 $\alpha$ , p110 $\beta$ , or p110 $\delta$  in the BaF3 cells was confirmed by western blotting (Figures 5A–5D). Unlike wild-type p85 $\alpha$ , all of the p85 $\alpha$  mutants tested promoted IL3-independent BaF3 cell survival either on their own or in combination with p110 $\alpha$ , p110 $\beta$ , or p110 $\delta$  (Figures 5A–5H). This survival benefit was blocked by a p110 $\alpha/\delta$  or a p110 $\beta$  (TGX-221) inhibitor (Folkes et al., 2007; Jackson et al., 2005), confirming the requirement of p110 activity for the observed p85 $\alpha$  mutant-mediated survival effect (Figures 5E–5H). Given that elevated class IA



**Figure 4. p85 $\alpha$  Mutants Are Impaired in Regulating Class IA PI3K Activity**

(A, C, and E) Dot blots show the amount of phosphorylated lipid generated by each of the tested heterodimeric enzymes in triplicates.

(B, D, and F) Mean  $\pm$  SEM of the amount of phosphorylated lipid generated in (A), (C), and (E) by each of the enzyme complexes in arbitrary units. Elevated PI3K activity is effectively inhibited by a p110 $\alpha$ / $\delta$  (B and F) or p110 $\beta$  (TGX-221; D) inhibitor (Folkes et al., 2007; Jackson et al., 2005). Mean  $\pm$  SEM percentage of control (p85 $\alpha$ -WT) activity is shown. \*p < 0.05, \*\*p < 0.01, and \*\*\*p < 0.001.

expressing wild-type p85 $\alpha$  or empty vector (Figure 6H). Consistent with this, MEFs expressing mutant p85 $\alpha$  showed a higher basal level of pAKT/AKT (Figure 6H and Figure S10E). Taken together, these data indicate that the iSH2 p85 $\alpha$  mutations do not affect p85 $\alpha$ -mediated p110 stabilization, but impair p85 $\alpha$ 's ability to negatively regulate class IA PI3Ks, leading to AKT-mediated cell survival and proliferation.


#### p85 $\alpha$ Mutants Promote Oncogenesis In Vivo

BaF3 cells that stably express oncogenic p110 $\alpha$  mutants promote leukemia and reduced survival when transplanted into mice (Horn et al., 2008). Since the p85 $\alpha$  mutants promote BaF3 cell survival, anchorage-independent growth, and pro-

liferation in vitro in a p110-dependent manner (Figures 5 and 6), we tested p85 $\alpha$ /p110 $\alpha$  eGFP/dsRed-tagged BaF3 cells for induction of leukemia-like disease in mice. Mice transplanted with BaF3 cells expressing mutant p85 $\alpha$  subunit together with wild-type p110 $\alpha$  showed a median survival of 30 to 40 days (Figure 7A). With the exception of one animal that received cells expressing p110 $\alpha$  alone, all mice that received BaF3 cells expressing either wild-type p85 $\alpha$  or coexpressing wild-type p85 $\alpha$  and p110 $\alpha$  or that had been transduced with empty vector were still alive at the end of the 55 day study period. Necropsies were conducted at 30 days on an additional cohort of three mice per treatment to follow disease progression. Bone marrow, spleen, and liver samples from these animals were reviewed for any pathological abnormalities. As the BaF3 cells were tagged with eGFP and/or dsRed, we examined isolated bone marrow for infiltrating cells by fluorescence-activated cell sorting (FACS). The bone marrow from mice transplanted with cells expressing mutant p85 $\alpha$  showed a significant proportion of infiltrating eGFP/dsRed-positive cells compared with bone marrow from mice receiving wild-type p85 $\alpha$  or empty vector control cells (Figures 7B and 7C). Consistent with the FACS data, in mice receiving cells expressing mutant p85 $\alpha$ , histological evaluation of spleen and liver stained with hematoxylin and eosin (H&E)

PI3K enzyme activity normally results in activation of downstream, prosurvival kinase AKT (Engelman et al., 2006), we tested the stable BaF3 cells expressing the mutant p85 $\alpha$  for the phospho-AKT (pAKT) levels following IL3 withdrawal. Consistent with the ability of the mutants to promote cell survival, cells that expressed p85 $\alpha$  mutants had increased pAKT when compared to cells expressing wild-type p85 $\alpha$  (Figures 5A–5D and Figures S10A–S10D).

In addition to cell survival, the p85 $\alpha$  mutants D560Y, N564D, N564D\_D560Y, and QYL579delL also promoted anchorage-independent growth of BaF3 cells in a class IA PI3K activity-dependent manner that was blocked by PI3K inhibitors (Figures 6A–6F). To further confirm that the p85 iSH2 C2 contact mutants were unable to inhibit p110 activity, we stably reconstituted the expression of the p85 $\alpha$  mutants in pan-p85 null MEFs (Brachmann et al., 2005) using a retroviral vector. As observed in our transient reconstitution studies (Figure 2E), all the p85 $\alpha$  mutants stabilized the expression of endogenous p110 $\alpha$  similar to wild-type p85 $\alpha$  (Figure 6G). In addition to stabilizing p110 $\alpha$ , wild-type and mutant p85 $\alpha$  expression also stabilized p110 $\beta$  and p110 $\delta$  (Figure 6G). Also, MEFs expressing D560Y, N564D, D560Y\_N564D, QYL579delL, and the Q572\* murine mutant showed an increase in proliferation when compared to MEFs



**Figure 5. p85 $\alpha$  Mutants Promote p110-Dependent Cell Survival and AKT Signaling**

(A–H) Stable expression p85 $\alpha$  mutants alone (A and E) or together with p110 $\alpha$  (B and F), p110 $\beta$  (C and G), or p110 $\delta$  (D and H) promote IL3-independent survival of BaF3 cells (E–H) and elevated pAKT (A–D) levels. The cell survival effects (E–H) of p85 $\alpha$  mutants are inhibited by a p110 $\alpha/\delta$  or p110 $\beta$  (TGX-221) inhibitor (Folkles et al., 2007; Jackson et al., 2005). Data shown in (E–H) are mean  $\pm$  SEM of at least three independent experiments with multiple replicates. \* $p < 0.05$  and \*\* $p < 0.01$ .


showed significant infiltration of blasts (Figure 7D). However, in mice receiving cells expressing wild-type p85 $\alpha$  or empty vector-transduced cells, there was little or no evidence of blast infiltration (Figure 7D). Mice carrying the mutant p85 $\alpha$ /p110 $\alpha$ -expressing cells also showed increased spleen and liver weight, which is consistent with an infiltration of cells into the liver and spleen (Table 1). These results demonstrate the *in vivo* leukemogenic potential conferred by the p85 $\alpha$  mutants on hematopoietic cells.

## DISCUSSION

Mutations in the p110 $\alpha$  catalytic subunit of PI3K are common in colon cancers (Samuels et al., 2004). In this study, we have identified the occurrence of frequent p85 $\alpha$  regulatory subunit mutations in colon cancer. The p85 $\alpha$  mutants were unable to negatively regulate p110 $\alpha$ , p110 $\beta$ , and p110 $\delta$  activity, despite retaining their ability to stabilize them. Of particular interest is a group of mutations in p85 $\alpha$  at the interface between p85 $\alpha$ -iSH2 and C2 domain of p110 $\alpha$  described in a recent crystal structure (Huang et al., 2007; TCGA, 2008). The mutated residues in p85 $\alpha$  N564 and D560 are within hydrogen bond distance of residue N345 in p110 $\alpha$ , which, when mutated, renders p110 $\alpha$  oncogenic (Gymnopoulos et al., 2007). These iSH2 mutations

mimic the effects of substitutions at N345 C2 domain of p110 $\alpha$  in that they promote elevated p110 $\alpha$  activity and therefore cell survival. *In vivo*, these mutants were capable of promoting oncogenesis, confirming the relevance of these mutants in colon cancer and glioblastoma. In addition, mutation at Q579 within the iSH2 also confers properties similar to mutations at N564 or D560, although the structural implication of this mutation remains to be understood. Taken together with the previously described murine Q572\* mutant (Jimenez et al., 1998), these findings suggest that this region of iSH2 is a potential hotspot for the accumulation of p85 $\alpha$  mutations that confer a cellular growth advantage.

Though oncogenic mutations in p110 $\alpha$  are common, such mutations in other class IA PI3Ks, p110 $\beta$  and p110 $\delta$ , are not common (Bader et al., 2005; Samuels et al., 2004). The p85 $\alpha$  subunit, besides interacting and regulating p110 $\alpha$ , can heterodimerize with p110 $\beta$  and p110 $\delta$  and regulate their activity (Chantray et al., 1997; Engelman et al., 2006; Hu et al., 1993; Vanhaesebroeck et al., 2005). Consistent with this, as observed with p110 $\alpha$ , we found that the p85 $\alpha$  mutants were able to interact and stabilize both p110 $\beta$  and p110 $\delta$ . However, the p85 $\alpha$  mutants were impaired in the ability to negatively regulate p110 $\beta$  and p110 $\delta$  activity. This is supported by our structural modeling and the proposal in a recent review (Amzel et al., 2008), which



**Figure 6. p85 $\alpha$  Mutants Promote Anchorage-Independent Growth, p110 Stabilization, and Proliferation**

(A–F) A representative image showing anchorage-independent growth (A–C) and number of colonies formed in the absence or presence of PI3K inhibitors (D–F) by BaF3 cells stably expressing p85 $\alpha$  mutants together with p110 $\alpha$  (A), p110 $\beta$  (B), or p110 $\delta$  (C).

(G and H) Pan-p85 null MEFs stably reconstituted with p85 $\alpha$  mutants show stabilization of p110 $\alpha$ , p110 $\beta$ , and p110 $\delta$  (G), elevated pAKT (G), and increased cell proliferation (H). Data shown (D–F and H) are mean  $\pm$  SEM. \* $p < 0.05$  and \*\* $p < 0.01$ .

suggest the presence of a conserved set of regulatory interactions between p110-C2 iSH2-p85 $\alpha$  across all three class IA PI3Ks. Our findings indicated that mutations in p85 $\alpha$  could serve as a global mechanism for deregulation of class IA PI3K activity in cancers. This is consistent with the emerging role of p110 $\beta$  and p110 $\delta$  in cancer (Kang et al., 2006; Zhao and Vogt, 2008).

Besides deregulation of class IA PI3K activity by the p85 $\alpha$  mutants, the impact of the p85 $\alpha$  mutations on p110-independent p85 $\alpha$  functions (Garcia et al., 2006; Taniguchi et al., 2006), the role of the additional p85 $\alpha$  mutants, and the activity of co-occurring p85 $\alpha$ /p110 $\alpha$  double mutant enzymes may all contribute to pathogenesis and remain to be explored. In gliomas, where p110 $\alpha$  mutations are not common (Bader et al., 2005), our data on the function of p85 $\alpha$  mutations indicate that such mutants may play a major role for PI3K pathway activation, in addition to *PTEN* inactivation (Parsons et al., 2008; TCGA, 2008; Yin and Shen, 2008).

Taken together, our data show that *PIK3R1* is a frequently mutated, functionally relevant colon cancer gene. Consistent


with our findings, a recent forward genetic screen in mouse for colon cancer genes identified *PIK3R1* as a site of transposon insertion in several independent lines (Starr et al., 2009). With the identification of *PIK3R1* mutations and the establishment of their functional relevance, it is very likely that the p85 mutations when used as biomarkers should allow the detection of p110-dependent p85 mutant tumors that are very likely to respond to treatment with inhibitors that target PI3Ks or their downstream effectors, such as AKT.

## EXPERIMENTAL PROCEDURES

### Tumor DNA, Mutation, and Genomic Amplification

Primary human tumor samples with appropriate IRB approval and patient informed consent were obtained from commercial sources (Table S1). The human tissue samples used in the study were de-identified (double-coded) prior to their use and hence the study using these samples is not considered human subject research under the US Department of Human and Health Services regulations and related guidance (45 CFR, Part 46). Tumor content in all the tumors used was confirmed to be >70% by pathology review. Tumor





**Figure 7. p85 $\alpha$  Mutants Lead to Reduced Overall Survival**

(A) Kaplan-Meier survival curves for cohorts of mice implanted with p85 $\alpha$  mutant expressing BaF3 cells compared to vector control cells or p85 $\alpha$  wild-type cells or p110 $\alpha$  cells alone or p85 $\alpha$ /p110 $\alpha$  cells showed a significant reduction in overall survival ( $n = 10$  for each arm; Log-rank test,  $p < 0.0001$ ).

(B) Flow cytometric analysis of total bone marrow isolated from mice receiving GFP- and/or dsRed-tagged BaF3 cells expressing the various p85 $\alpha$  mutants.

(C) Mean number of GFP- and/or dsRed-positive cells in the bone marrow of mice ( $n = 3$ ) that received BaF3 cells expressing p85 $\alpha$  mutants. Values are mean  $\pm$  SEM.

(D) Representative H&E-stained liver (top) and spleen (bottom) sections from the same mice analyzed in (B). Arrows indicate tumor cells infiltrating the liver. R, red pulp; W, lymphoid follicles of white pulp. In unmarked spleen section, there is a loss of red/white pulp architecture due to disruption by infiltrating tumor cells. Scale bar corresponds to 100  $\mu$ m.

DNA was extracted using QIAGEN Tissue easy kit (QIAGEN). All coding exons of *PIK3R1-R5*, *PIK3CA*, *KRAS*, and *PTEN* were amplified using primers listed in Table S4 and sequenced using 3730xl ABI sequencer (Applied Biosystems). The PCR products were generated using two pairs of primers, an outer pair and an inner pair, to increase the specificity (Table S4), using standard PCR conditions. The sequencing data was analyzed for presence of protein variants not present in the dbSNP database using Mutation Surveyor (Softgenetics) and additional automated sequence alignment programs. The putative variants identified were confirmed for their presence by DNA sequencing or mass spectrometry analysis (Sequenom) of the original tumor DNA followed by confirmation of its absence in the adjacent matched normal DNA by a similar process applied to the tumor DNA (Figures S1 and S2).

The C2 homology models we generated by ESyPred3D (Lambert et al., 2002) server, using C2 domain sequences and the crystal structure of P110 $\alpha$  (PDB: 2RD0) as a template. The initial homology model was then improved

by manual adjustment and geometric optimization with COOT (Emsley and Cowtan, 2004).

Genomic DNA from tumor samples as annotated in Table S1 was analyzed using an Affymetrix GeneChip mapping 100,000 arrays (Affymetrix) as per the manufacturer's instructions. Copy number data were generated for each array by using the Affymetrix Chromosome Copy Number Tool (CNAT) v.2.0 (Huang et al., 2004) and/or dChipSNP (Lin et al., 2004).

#### Cell Lines

The IL-3-dependent mouse pre-B cell line BaF3 and Cos7 cells were purchased from American Type Culture Collection. BaF3 cells were maintained in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Thermo Fisher Scientific), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (complete RPMI), and 2 ng/ml mouse IL-3. The p85 $\alpha$  and  $\beta$  knockout mouse embryonic fibroblasts (Pan-p85 MEFs) were obtained from L.C. Cantley's laboratory (Harvard Medical School) and maintained in DMEM

**Table 1. Characterization of BAF3-p85 $\alpha$  Implanted Mice**

Transplanted Cells	Weights		
	Body	Spleen	Liver
Empty vector	20.9 $\pm$ 0.7	0.44 $\pm$ 0.11	1.17 $\pm$ 0.24
P85 $\alpha$ -WT	20.3 $\pm$ 0.4	0.11 $\pm$ 0.01	1.16 $\pm$ 0.01
P110 $\alpha$ -WT	22.1 $\pm$ 0.9	0.21 $\pm$ 0.05	1.15 $\pm$ 0.01
P85 $\alpha$ -WT + p110 $\alpha$ -WT	20.3 $\pm$ 0.4	0.11 $\pm$ 0.01	1.37 $\pm$ 0.01
P85 $\alpha$ -D560Y + p110 $\alpha$ -WT	20.9 $\pm$ 0.8	1.18 $\pm$ 0.15**	2.87 $\pm$ 0.30**
P85 $\alpha$ -N564D + p110 $\alpha$ -WT	20.9 $\pm$ 0.5	0.97 $\pm$ 0.14**	2.88 $\pm$ 0.49**
P85 $\alpha$ D560Y_N564D + p110 $\alpha$ -WT	21.3 $\pm$ 0.3	0.87 $\pm$ 0.03**	2.51 $\pm$ 0.32**

Balb/C mice received  $2 \times 10^6$  BAF3 cells stably expressing p110 $\alpha$  wild-type (p110 $\alpha$ -WT) and p85 $\alpha$  wild-type (p85 $\alpha$ -WT) or mutants (n = 3) or the vector (n = 3) by tail-vein injection. Allografted mice were sacrificed 5 weeks after transplantations and tissues were collected and analyzed.

\*\*p < 0.01 versus p85 $\alpha$ -WT + p110 $\alpha$ -WT.

supplemented with 15% (v/v) fetal bovine serum, while Cos7 cells were maintained in DMEM supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Phoenix (Orbigen) cells were maintained in DMEM supplemented with 10% FBS. *Spodoptera frugiperda* (Sf9) insect cells (Vaughn et al., 1977) were grown in ESF 921 serum-free medium (Expression systems LLC).

#### Plasmids and Antibodies

Eukaryotic expression plasmid pRK5E, driving the expression of HA-p85 $\alpha$  mutants, untagged p110 $\alpha$ , N-myc-tagged p110 $\alpha$ , N-myc-tagged p110 $\beta$ , and N-myc-tagged p110 $\delta$  were constructed using standard PCR and cloning strategies. pRetro-IRESdsRed (Clontech) or a version of this retroviral vector with GFP in place of dsRed was used to stably express HA-p85 $\alpha$ , N-myc-p110 $\alpha$  (Yu et al., 1998), N-myc-p110 $\beta$ , and N-myc-p110 $\delta$ . Recombinant baculovirus expressing N-His $_6$ -p110 $\alpha$ , N-His $_6$ -p110 $\beta$ , N-His $_6$ -p110 $\delta$ , and untagged p85 $\alpha$  driven by the polyhedrin promoter were prepared according to the manufacturer's recommendations using the Bac-to-Bac Expression System (Invitrogen). GST fusion constructs expressing p85 nSHi made of amino acids 320–600 (Shekar et al., 2005) was made in pGEX6p-2 (GE Healthcare).

Antibodies that recognize pAKT (Ser473) and AKT (Cell Signaling Technology), p110 $\beta$  (Cell Signaling Technology), p110 $\alpha$  and p110 $\delta$  (Epitomics), c-Myc (Genentech Inc.), and  $\beta$ -actin and Flag M2 (Sigma-Aldrich) were used in the study. Horseradish peroxidase (HRP)-conjugated HA antibody (Roche Molecular Biochemicals) and HRP-conjugated secondary antibodies (Pierce Biotechnology) were used in western blots. Anti-HA rat monoclonal (clone 3F10)-coupled affinity matrix (Roche Diagnostics) and c-Myc tag IP application kit (Thermo Fisher Scientific) were used for immunoprecipitation studies.

#### Recombinant Proteins

To generate recombinant heterodimeric PI3K enzyme, 1 liter of  $2 \times 10^6$  Sf-9 cells/ml was co-infected with either p110 $\alpha$  or p110 $\beta$  or p110 $\delta$  and p85 $\alpha$  expressing baculoviruses at a multiplicity of infection of 0.5 each. Cell pellets were harvested at 72 hr after infection and lysed in lysis buffer A [50 mM Tris HCl (pH 8.0), 0.3 M NaCl, 20 mM Imidazole, 1 mM TCEP, and protease inhibitors]. The cell lysate was clarified by spinning at 35,000  $\times$  g for 1 hr at 4°C. The clarified supernatant was loaded over a Ni-NTA Superflow (QIAGEN) column pre-equilibrated with lysis buffer A. The His $_6$ P110 $\alpha$ /p85 $\alpha$  complex was eluted using imidazole gradient (20 mM to 250 mM) made using buffer B [20 mM Tris HCl (pH 8.0), 0.3 M NaCl, and 0.25 mM TCEP]. The purified His $_6$ P110/p85 $\alpha$  was further purified on a Superdex 200 size exclusion column pre-equilibrated with 25 mM Tris (pH 7.5), 150 mM NaCl, 0.25 mM TCEP, and 10% glycerol. Purified proteins were serially diluted and resolved on SDS-containing PAGE for concentration assessment (Figure S11).

BL-21 *E. coli* cells transformed with the appropriate pGEX6p-2 nSHi expression construct were induced to express GST fusion proteins as per the manufacturer's recommendations. Cell pellet from 1 liter culture was lysed in lysis buffer C (PBS, 2 mM DTT, and protease inhibitors), microfluidized, and centri-

fuged at 35,000  $\times$  g for 1 hr at 4°C. Clarified lysate was loaded over a GST-Sepharose 4 fast flow (GE Healthcare) column pre-equilibrated with lysis buffer C. Bound GST-p85 nSHi was eluted using buffer B [50 mM Tris (pH 8.0), 10 mM NaCl, 1 mM EDTA, 2 mM DTT, and 10 mM GSH]. Eluted proteins were dialyzed into buffer D [20 mM Tris (pH 8), 150 mM NaCl, 1 mM EDTA, and 0.25 mM TCEP] and incubated with PreScission protease (GE Healthcare) at 4°C overnight to remove the GST tag. The untagged p85 nSHi in the dialyzed and digested material was recovered by passing it over a GST-Sepharose column. The nSHi protein was further purified by size exclusion on a Superdex 200 column.

#### Generation of Stable Cell Lines

Retroviral constructs expressing HA-p85-dsRed and/or myc-p110-GFP were transfected into Phoenix amphoteric cells using Lipofectamine (Invitrogen). The resulting virus was then transduced into BAF3 cells and pan-p85 null MEFs. The top 10% of the infected cells based on the expression of retroviral IRES-driven dsRed and/or GFP were sterile sorted by flow cytometry and characterized for expression of proteins by western blot. Pools of these cells were then used in further studies.

#### Immunoprecipitation and Western Blot

Cos-7 ( $2.5 \times 10^5$ ) or pan-p85 null MEFs ( $10 \times 10^6$ ) cells were transfected or nucleofected with appropriate constructs expressing HA-p85 and/or p110 wild-type DNA using Fugene 6 (Roche diagnostics) or nucleofection kit 1 (Amaza Inc.) following the manufacturer's protocol. At 48 hr posttransfection/nucleofection, cells were washed with PBS and lysed in a lysis buffer I [50 mM Tris HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100]. The clarified lysates were incubated for 2 hr at 4°C with anti-HA antibody coupled beads. The HA beads were then spun down at 500  $\times$  g for 2 min and washed thrice using the lysis buffer I. The immunoprecipitated proteins remaining on the beads were boiled in SDS-PAGE loading buffer, resolved on a 4%–20% SDS-PAGE (Invitrogen), and transferred onto a nitrocellulose membrane. Immunoprecipitated proteins or proteins from lysates were detected using appropriate primary, HRP-conjugated secondary antibody, and chemiluminescence Super signal West Dura chemiluminescence detection substrate (Thermo Fisher Scientific).

#### Survival and Proliferation Assay

For the initial characterization of the p85 $\alpha$  mutants,  $2 \times 10^6$  BAF3 cells were nucleofected with appropriate pRK5E wild-type or mutant constructs expressing HA-p85 $\alpha$  and/or myc-p110 $\alpha$  DNA using nucleofection kit V (Amaza Inc.). After a 3 hr recovery period in media without IL-3 following nucleofection cells were plated in 3  $\times$  96 well plates in triplicates and monitored for survival. Similarly, BAF3 cells stably expressing the wild-type and mutant p85 $\alpha$  alone or together with myc-p110 $\alpha$ , myc-p110 $\beta$ , or myc-p110 $\delta$  were washed twice in PBS and plated in 3  $\times$  96 well plates in replicates of twelve in complete RPMI medium without IL3. 500 nM of the p110 small molecule inhibitor PI3Ki-A/D (Folkes et al., 2007) or TGX-221 (Jackson et al., 2005) in 0.1% DMSO was used to test the effects of p110 inhibition where relevant, as depicted in the figures. Viable cells at 0, 24, 48, 96, and 120 hr were determined using Cell Titer-Glo luminescence cell viability kit (Promega Corp.) and Synergy 2 (Biotek Instrument) luminescence plate reader. All the cell number values were normalized against 0 hr values. Normalized vector control cell value was used to calculate the relative survival of the various mutant p85 $\alpha$  either alone or in combination with class IA PI3Ks. In order to assess proliferation of pan-p85 null MEFs stably expressing p85 $\alpha$  wild-type or mutants, 5000 cells in triplicates were plated in media with 15% serum and allowed to proliferate for 5 days. Cell numbers were measure at day 0 and day 5 using the luminescence cell viability kit. Data was expressed as mean  $\pm$  SEM of fold change over vector or p85 wild-type. Mean and statistical significance was determined using GraphPad V software (GraphPad).

#### In Vitro PI3K Activity Assay

Purified PI3K heterodimeric enzyme was quantified on a gel to estimate the concentration of p85 $\alpha$  along with either p110 $\alpha$ , p110 $\beta$ , or p110 $\delta$  (Figure S11). For each of the p110/p85 $\alpha$  purified enzyme combination, 30 ng of the purified protein was tested for PI3K activity as described recently (Knight et al., 2007). Briefly, 30 ng of each of the purified enzyme was incubated for 30 min at 25°C with PI and 2  $\mu$ Ci [ $\gamma$ -<sup>32</sup>P] ATP (PerkinElmer) in 25  $\mu$ l of kinase reaction buffer

[10  $\mu$ M ATP, 1 mg/ml BSA, 25 mM HEPES (pH 7.4), and 10 mM MgCl<sub>2</sub>] either with or without 500 nM PI3K $\alpha$ /D or TGX-221. At the end of 30 min, 4  $\mu$ l of each reaction was spotted onto a dry nitrocellulose membrane (Bio-Rad Laboratories) using a multichannel pipette and was dried and washed five times with wash solution (1 M NaCl in 1% H<sub>3</sub>PO<sub>4</sub>). After the washes the membrane was dried and exposed to a phosphor screen for 1 hr. The exposed phosphor screen was then scanned on a Typhoon phosphorimager (GE Healthcare). The amount of bound radioactive lipid derived from PI phosphorylation by the different PI3K enzymes studied was quantified using a MATLAB script called Spot (Knight et al., 2007). Alternatively, inhibition of recombinant p110 $\alpha$  in baculovirus lysates by *E. coli*-expressed and -purified p85 $\alpha$  nSHI was directly measured as described previously (Shekar et al., 2005).

#### BaF3 Colony Formation Assay

BaF3 cells ( $2 \times 10^5$ ), stably expressing p110 $\alpha$ , p110 $\beta$ , or p110 $\delta$  along with p85 $\alpha$  wild-type or mutants, was mixed with 2 ml of IL3-free Methocult (STEMCELL Technologies) with or without 500 nM PI3K $\alpha$ /D or TGX-221 and plated on to 6 well plates that were then incubated at 37°C for 2 weeks. The presence of colonies was assessed using Gel count imager (Oxford Optronix Ltd.). The number of colonies in each plate was quantified using Gel count software (Oxford Optronix Ltd.).

#### Animal Studies

BaF3 cells ( $2 \times 10^6$ ) expressing the p85 $\alpha$  wild-type or mutants along with p110 $\alpha$  were implanted into 8–12 week old Balb/C nude mice by tail vein injection. A total of 13 animals per treatment were injected. Of this, ten mice were followed for survival and three were used for necropsy at day 30 to assess disease progression by histological analysis of spleen and liver. Bone marrow single cell suspension obtained from these animals was also analyzed for the presence and proportion of GFP- and/or dsRed-positive BaF3 cells by FACS analysis. When possible, dead or moribund animals in the survival study were dissected to confirm the cause of death. Morphological and histological analyses of spleen, liver, and bone marrow was also done on these animals. Spleen and liver were fixed in 10% neutral-buffered formalin, and then processed in an automated tissue processor (TissueTek) and embedded in paraffin. Four micrometer thick sections were stained with H&E (Sigma-Aldrich) and analyzed histologically for presence of infiltrating tumor cells. Photographs of histology were taken on a Nikon 80i compound microscope with a Nikon DS-R camera. All animal studies were performed under Genentech's Institutional Animal Care and Use Committee approved protocols.

#### Statistical Analyses

Student's t test (two tailed) was used for statistical analyses to compare treatment groups using GraphPad Prism 5.00 (GraphPad Software). A p value <0.05 was considered statistically significant (\*p < 0.05, \*\*p < 0.01, and \*\*\*p < 0.001). For Kaplan-Meier Method of survival analysis, log-rank statistics were used to test for difference in survival.

#### ACCESSION NUMBERS

The array data from this study was deposited with Gene Expression Omnibus database under accession number GSE1852.

#### SUPPLEMENTAL DATA

Supplemental Data include eleven figures and four tables and can be found with this article online at [http://www.cell.com/cancer-cell/supplemental/S1535-6108\(09\)00385-7](http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00385-7).

#### ACKNOWLEDGMENTS

The authors would like to acknowledge Genentech DNA Sequencing, Oligo, Microarray, and FACS laboratories for their help with the project. We thank the Genentech Bioinformatics group for informatics infrastructure support and the Pathology Core Laboratories for providing histology, immunohistochemistry, and tissue management support. Thanks to C. Dant, R. Kelly, K. Newton, and J. Theunissen for their critical reading of the manuscript. Work

in J.M.B.'s laboratory was supported by a grant from the Janey Fund and National Institutes of Health grant GM55692. Special thanks to L.C. Cantley for the pan-p85 null MEFs. The majority of the authors are employees of Genentech Inc., as indicated.

Received: April 28, 2009

Revised: August 18, 2009

Accepted: October 19, 2009

Published: December 7, 2009

#### REFERENCES

- Amzel, L.M., Huang, C.H., Mandelker, D., Lengauer, C., Gabelli, S.B., and Vogelstein, B. (2008). Structural comparisons of class I phosphoinositide 3-kinases. *Nat. Rev. Cancer* 8, 665–669.
- Backer, J.M., Myers, M.G., Jr., Shoelson, S.E., Chin, D.J., Sun, X.J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E.Y., Schlessinger, J., et al. (1992). Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation. *EMBO J.* 11, 3469–3479.
- Bader, A.G., Kang, S., Zhao, L., and Vogt, P.K. (2005). Oncogenic PI3K deregulates transcription and translation. *Nat. Rev. Cancer* 5, 921–929.
- Borlado, L.R., Redondo, C., Alvarez, B., Jimenez, C., Criado, L.M., Flores, J., Marcos, M.A., Martinez, A.C., Balomenos, D., and Carrera, A.C. (2000). Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. *FASEB J.* 14, 895–903.
- Brachmann, S.M., Yballe, C.M., Innocenti, M., Deane, J.A., Fruman, D.A., Thomas, S.M., and Cantley, L.C. (2005). Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. *Mol. Cell. Biol.* 25, 2593–2606.
- Cantley, L.C. (2002). The phosphoinositide 3-kinase pathway. *Science* 296, 1655–1657.
- Carpenter, C.L., Auger, K.R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., and Cantley, L.C. (1993). Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. *J. Biol. Chem.* 268, 9478–9483.
- Chan, T.O., Rodeck, U., Chan, A.M., Kimmelman, A.C., Rittenhouse, S.E., Panayotou, G., and Tschlis, P.N. (2002). Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. *Cancer Cell* 1, 181–191.
- Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D.A., Wood, C., Gray, P.W., Cooper, J.A., and Hoekstra, M.F. (1997). p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. *J. Biol. Chem.* 272, 19236–19241.
- Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M.J., Yonezawa, K., Kasuga, M., and Waterfield, M.D. (1994). PI 3-kinase: structural and functional analysis of intersubunit interactions. *EMBO J.* 13, 511–521.
- Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* 60, 2126–2132.
- Engelman, J.A., Luo, J., and Cantley, L.C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat. Rev. Genet.* 7, 606–619.
- Folkes, A., Shuttleworth, S., Chuckowree, I., Oxenford, S., Wan, N.C., Castaneda, G., Goldsmith, R., Gunzner, J., Heffron, T., Mathieu, S., et al. August 2007. Preparation of thienopyrimidines and furopyrimidines as lipid kinase inhibitors for treating cancer and other diseases. Patent PIXD2 WO 2007127175.
- Fruman, D.A., Meyers, R.E., and Cantley, L.C. (1998). Phosphoinositide kinases. *Annu. Rev. Biochem.* 67, 481–507.
- Garcia, Z., Silio, V., Marques, M., Cortes, I., Kumar, A., Hernandez, C., Checa, A.I., Serrano, A., and Carrera, A.C. (2006). A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis. *EMBO J.* 25, 4740–4751.
- Gymnopoulos, M., Elsliger, M.A., and Vogt, P.K. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. *Proc. Natl. Acad. Sci. USA* 104, 5569–5574.



- Hartmann, C., Bartels, G., Gehlhaar, C., Holtkamp, N., and von Deimling, A. (2005). PIK3CA mutations in glioblastoma multiforme. *Acta Neuropathol.* 109, 639–642.
- Hawkins, P.T., Anderson, K.E., Davidson, K., and Stephens, L.R. (2006). Signalling through Class I PI3Ks in mammalian cells. *Biochem. Soc. Trans.* 34, 647–662.
- Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat. Rev. Drug Discov.* 4, 988–1004.
- Hoedemaeker, F.J., Siegal, G., Roe, S.M., Driscoll, P.C., and Abrahams, J.P. (1999). Crystal structure of the C-terminal SH2 domain of the p85 $\alpha$  regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate. *J. Mol. Biol.* 292, 763–770.
- Holt, K.H., Olson, L., Moye-Rowley, W.S., and Pessin, J.E. (1994). Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. *Mol. Cell. Biol.* 14, 42–49.
- Horn, S., Bergholz, U., Jucker, M., McCubrey, J.A., Trumper, L., Stocking, C., and Basecke, J. (2008). Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. *Oncogene* 27, 4096–4106.
- Hu, P., Mondino, A., Skolnik, E.Y., and Schlessinger, J. (1993). Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. *Mol. Cell. Biol.* 13, 7677–7688.
- Huang, C.H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V.E., Kinzler, K.W., Vogelstein, B., Gabeli, S.B., and Amzel, L.M. (2007). The structure of a human p110 $\alpha$ /p85 $\alpha$  complex elucidates the effects of oncogenic PI3K $\alpha$  mutations. *Science* 318, 1744–1748.
- Huang, C.H., Mandelker, D., Gabeli, S.B., and Amzel, L.M. (2008). Insights into the oncogenic effects of PIK3CA mutations from the structure of p110 $\alpha$ /p85 $\alpha$ . *Cell Cycle* 7, 1151–1156.
- Huang, J., Wei, W., Zhang, J., Liu, G., Bignell, G.R., Stratton, M.R., Futreal, P.A., Wooster, R., Jones, K.W., and Shaper, M.H. (2004). Whole genome DNA copy number changes identified by high density oligonucleotide arrays. *Hum. Genomics* 1, 287–299.
- Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005). Functional analysis of PIK3CA gene mutations in human colorectal cancer. *Cancer Res.* 65, 4562–4567.
- Isakoff, S.J., Engelman, J.A., Irie, H.Y., Luo, J., Brachmann, S.M., Pearlman, R.V., Cantley, L.C., and Brugge, J.S. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. *Cancer Res.* 65, 10992–11000.
- Jackson, S.P., Schoenwaelder, S.M., Goncalves, I., Nesbitt, W.S., Yap, C.L., Wright, C.E., Kenche, V., Anderson, K.E., Dopheide, S.M., Yuan, Y., et al. (2005). PI 3-kinase p110 $\beta$ : a new target for antithrombotic therapy. *Nat. Med.* 11, 507–514.
- Jimenez, C., Hernandez, C., Pimentel, B., and Carrera, A.C. (2002). The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. *J. Biol. Chem.* 277, 41556–41562.
- Jimenez, C., Jones, D.R., Rodriguez-Vician, P., Gonzalez-Garcia, A., Leonardo, E., Wennstrom, S., von Kobbe, C., Toran, J.L., R-Borlodo, L., Calvo, V., et al. (1998). Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. *EMBO J.* 17, 743–753.
- Jucker, M., Sudel, K., Horn, S., Sickel, M., Wegner, W., Fiedler, W., and Feldman, R.A. (2002). Expression of a mutated form of the p85 $\alpha$  regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). *Leukemia* 16, 894–901.
- Kang, S., Bader, A.G., and Vogt, P.K. (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc. Natl. Acad. Sci. USA* 102, 802–807.
- Kang, S., Denley, A., Vanhaesebroeck, B., and Vogt, P.K. (2006). Oncogenic transformation induced by the p110 $\beta$ , - $\gamma$ , and - $\delta$  isoforms of class I phosphoinositide 3-kinase. *Proc. Natl. Acad. Sci. USA* 103, 1289–1294.
- Knight, Z.A., Feldman, M.E., Balla, A., Balla, T., and Shokat, K.M. (2007). A membrane capture assay for lipid kinase activity. *Nat. Protoc.* 2, 2459–2466.
- Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Vician, P., Downward, J., and Parker, P.J. (1994). The activation of phosphatidylinositol 3-kinase by Ras. *Curr. Biol.* 4, 798–806.
- Lambert, C., Leonard, N., De Bolle, X., and Depiereux, E. (2002). ESyPred3D: Prediction of proteins 3D structures. *Bioinformatics* 18, 1250–1256.
- Lin, M., Wei, L.J., Sellers, W.R., Lieberfarb, M., Wong, S.H., and Li, C. (2004). dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. *Bioinformatics* 20, 1233–1240.
- Miled, N., Yan, Y., Hon, W.C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H.J., Backer, J.M., and Williams, R.L. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. *Science* 317, 239–242.
- Otsu, M., Hiles, I., Gout, I., Fry, M.J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., et al. (1991). Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. *Cell* 65, 91–104.
- Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Mani, P., Carter, H., Siu, I.M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. *Science* 321, 1807–1812.
- Philp, A.J., Campbell, I.G., Leet, C., Vincan, E., Rockman, S.P., Whitehead, R.H., Thomas, R.J., and Phillips, W.A. (2001). The phosphatidylinositol 3'-kinase p85 $\alpha$  gene is an oncogene in human ovarian and colon tumors. *Cancer Res.* 61, 7426–7429.
- Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. *Science* 304, 554.
- Shekar, S.C., Wu, H., Fu, Z., Yip, S.C., Nagajothi, Cahill, S.M., Girvin, M.E., and Backer, J.M. (2005). Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. *J. Biol. Chem.* 280, 27850–27855.
- Starr, T.K., Allaei, R., Silverstein, K.A., Staggs, R.A., Sarver, A.L., Bergemann, T.L., Gupta, M., O'Sullivan, M.G., Matise, I., Dupuy, A.J., et al. (2009). A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. *Science* 323, 1747–1750.
- Taniguchi, C.M., Tran, T.T., Kondo, T., Luo, J., Ueki, K., Cantley, L.C., and Kahn, C.R. (2006). Phosphoinositide 3-kinase regulatory subunit p85 $\alpha$  suppresses insulin action via positive regulation of PTEN. *Proc. Natl. Acad. Sci. USA* 103, 12093–12097.
- TCGA. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 455, 1061–1068.
- Vanhaesebroeck, B., and Waterfield, M.D. (1999). Signaling by distinct classes of phosphoinositide 3-kinases. *Exp. Cell Res.* 253, 239–254.
- Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., and Fokas, L.C. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. *Trends Biochem. Sci.* 30, 194–204.
- Vaughn, J.L., Goodwin, R.H., Tompkins, G.J., and McCawley, P. (1977). The establishment of two cell lines from the insect *Spodoptera frugiperda* (Lepidoptera; Noctuidae). *In Vitro* 13, 213–217.
- Wang, Z.J., Taylor, F., Churchman, M., Norbury, G., and Tomlinson, I. (1998). Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. *Am. J. Pathol.* 153, 363–366.
- Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. *Science* 318, 1108–1113.
- Yin, Y., and Shen, W.H. (2008). PTEN: a new guardian of the genome. *Oncogene* 27, 5443–5453.
- Yu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G.A., and Backer, J.M. (1998). Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110 $\alpha$  catalytic subunit by the p85 regulatory subunit. *Mol. Cell. Biol.* 18, 1379–1387.
- Zhao, L., and Vogt, P.K. (2008). Class I PI3K in oncogenic cellular transformation. *Oncogene* 27, 5486–5496.